Strategic Partnerships Merz Therapeutics is actively expanding through partnerships, including a recent alliance with Grünenthal in Brazil and ongoing activity in Greater China with Kvvit Pharmaceutical. Sales teams should target regional co-marketing and licensing opportunities, leverage joint clinical initiatives, and explore distribution collaborations to accelerate market access for INBRIJA and other neurology therapies.

Geographic Expansion The company operates in over 80 countries and is pursuing mainland China, Hong Kong, and Macao markets for INBRIJA, signaling strong demand for Parkinson’s disease management in these regions. Focus sales efforts on local regulatory support, payer landscape mapping, and clinician education programs to drive uptake in high-growth markets.

Product Focus INBRIJA (levodopa inhalation powder) is a key growth driver with exclusivity licensing activity in China and broader Greater China. Develop targeted access strategies with hospitals and neurology centers, emphasizing rapid ON motivation for PD patients and payer value propositions, while identifying potential line extensions or companion diagnostics to expand indication scopes.

Scientific Leadership Merz Therapeutics is presenting numerous scientific abstracts at ISPRM World Congress and maintains a strong research footprint. Sales teams can position the company as a knowledge leader to win clinical partnerships, sponsor expert-led education, and drive investigator-initiated studies that support product adoption and credibility in movement disorders and neurodegenerative conditions.

Brand and Campaigns Brand initiatives like Celebrating the Fighters in North America indicate an emphasis on patient-centric marketing for Parkinson’s disease. This presents opportunities to collaborate on patient engagement programs, digital campaigns, physician outreach, and caregiver support solutions that can enhance brand loyalty and accelerate product adoption.